New drug combo targets aggressive bone cancer in teens and young adults
NCT ID NCT05046314
Summary
This study tested an experimental drug called TK216, given with the chemotherapy drug vincristine, for people aged 14 and older with Ewing's sarcoma that has come back or stopped responding to other treatments. The main goal was to see if this combination could shrink tumors and control the disease. Researchers also closely monitored side effects to understand the safety of this new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, EWING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University Cancer Institude & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 100005, China
Conditions
Explore the condition pages connected to this study.